External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ASGCT Breakthroughs 2024

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Nov 19 / Roche and Genentech
Wearable Device Outcomes From EMBARK, a Pivotal Phase 3 Study in Patients With Duchenne Muscular Dystrophy Treated With Delandistrogene Moxeparvovec
We present analyses of wearable-derived ambulation endpoints from EMBARK Part 1 (52 weeks), including Stride Velocity 95th Centile (SV95C; secondary endpoint) and exploratory ambulation endpoints. Results demonstrated improved disease trajectories following treatment with delandistrogene moxeparvovec and supported stabilization or slowing of DMD disease progression compared with placebo, consistent with secondary functional endpoints in EMBARK.
02:00 PM
Duration 1hr Chicago, USA
Wearable Device Outcomes From EMBARK, a Pivotal Phase 3 Study in Patients With Duchenne Muscular Dystrophy Treated With Delandistrogene Moxeparvovec
Paul Strijbos, Craig McDonald, Alexander Murphy, Stefanie Mason, Xiao Ni, Carol Reid, Marianna Manfrini, Jacob Elkins, Louise Rodino-Klapac, Francesco Muntoni

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar